DSP-2230

DSP-2230 is an investigational small-molecule inhibitor of voltage-gated sodium channels, specifically targeting the Nav1.7, Nav1.8, and Nav1.9 subtypes. Developed by Sumitomo Pharma (formerly Dainippon Sumitomo Pharma) and its subsidiary Sunovion, the compound is designed for the treatment of peripheral neuropathic pain. These specific sodium channel subtypes are primarily expressed in peripheral sensory neurons and play critical roles in the transmission of pain signals. By selectively blocking these channels, DSP-2230 aims to provide analgesic effects with a reduced risk of central nervous system or cardiovascular side effects typically associated with non-selective sodium channel blockers. Clinical development has included Phase I studies in the United Kingdom evaluating safety, tolerability, and pharmacokinetics in both single and multiple ascending dose cohorts.